Game Creek Capital LP Trims Stake in Pfizer Inc. $PFE

Game Creek Capital LP cut its holdings in Pfizer Inc. (NYSE:PFE) by 23.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 127,500 shares of the biopharmaceutical company’s stock after selling 40,125 shares during the period. Pfizer accounts for 1.1% of Game Creek Capital LP’s portfolio, making the stock its 23rd largest holding. Game Creek Capital LP’s holdings in Pfizer were worth $3,249,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of PFE. Peak Asset Management LLC increased its stake in shares of Pfizer by 1.4% in the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after purchasing an additional 402 shares in the last quarter. Community Bank & Trust Waco Texas lifted its position in Pfizer by 0.6% during the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after purchasing an additional 412 shares in the last quarter. CVA Family Office LLC grew its holdings in Pfizer by 3.3% during the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after purchasing an additional 413 shares during the period. Boltwood Capital Management grew its holdings in Pfizer by 0.7% during the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock valued at $1,485,000 after purchasing an additional 420 shares during the period. Finally, Beverly Hills Private Wealth LLC increased its position in Pfizer by 1.5% in the third quarter. Beverly Hills Private Wealth LLC now owns 27,955 shares of the biopharmaceutical company’s stock worth $712,000 after buying an additional 421 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $26.60 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. The company’s fifty day moving average price is $26.50 and its 200-day moving average price is $25.52. Pfizer Inc. has a one year low of $20.92 and a one year high of $27.94. The company has a market capitalization of $151.23 billion, a PE ratio of 19.56 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s quarterly revenue was down 1.2% on a year-over-year basis. During the same period last year, the company posted $0.63 earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Barclays initiated coverage on Pfizer in a research report on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective on the stock. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. HSBC restated a “buy” rating and set a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $30.00 price objective on shares of Pfizer in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.05.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approves Pfizer’s GLP‑1 weight‑management drug Xianweiying, opening a large, fast‑growing market and adding a new commercial revenue stream in 2026+ — potential upside to international sales. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Promising Phase 2 results for tilrekimig (trispecific antibody) in atopic dermatitis reinforce Pfizer’s immunology pipeline; if confirmed in later trials, this could be a material franchise expansion. How Tilrekimig’s Trispecific Eczema Data At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer advanced an early‑stage oncology candidate (PF‑07994525), expanding its cancer pipeline and showing continued R&D momentum in higher‑value therapeutic areas. Pfizer Advances Early-Stage Cancer Candidate PF-07994525
• Positive Sentiment: Scotiabank reaffirmed a Buy rating on PFE, providing analyst support that can help stabilize sentiment among institutional holders. Scotiabank Sticks to Their Buy Rating for Pfizer (PFE)
• Neutral Sentiment: Market research reports highlight long‑acting growth‑hormone (Ngenla/somatrogon) market expansion and regional opportunities (Asia‑Pacific growth), useful for medium‑term planning but not immediate earnings. Ngenla (somatrogon: Pfizer) Market Research Report 2026
• Neutral Sentiment: Separate market research on Tivdak (tisotumab vedotin) underscores oncology demand and biomarker opportunities; supportive for long‑term growth but not an immediate catalyst. Tivdak (Genmab, Pfizer: tisotumab vedotin-tftv) Market Research Report 2026
• Neutral Sentiment: Industry reports on AI in life sciences list Pfizer among firms accelerating AI‑driven drug discovery; this supports long‑run efficiency gains but faces regulatory/cost adoption timelines. AI in Life Sciences Market, 2026-2040
• Negative Sentiment: Persistent headwinds — post‑COVID revenue normalization and drug‑pricing pressure — continue to weigh on sentiment; commentary urging buy due to a high dividend yield reflects a lower share‑price base rather than improving top‑line momentum. 1 Magnificent Dividend Stock Down 57% to Buy and Hold Forever
• Negative Sentiment: Short‑term sell pressure: outlets and data summaries note PFE has dipped more than the broader market in recent sessions, suggesting positioning/rotation risk for today’s weakness. Pfizer (PFE) Sees a More Significant Dip Than Broader Market

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.